Drugs / VX-118
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06312787 | Apr → May 2024 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06154447 | Dec 2023 → Jul 2026 overdue | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06312787 ↗ |
| Route | Oral | “Tablets for Oral Administration” NCT06154447 ↗ |